4th rna-seq san francisco april 26-28 event guide

April 26 - 28, 2016 San Francisco, CA

24 Expert Speakers Including:

Lead Partner: Additional Partners:

www.rna-seqsummit.comResearched & Developed By:

Tel: +1 212 537 5898 | Email: [email protected] RNA-Seq Forum

• HarnessingtheFullPotentialofSingle-CellRNA-Seq

• ReinventingAnalyticalStrategiestoDealwiththeVastComplexityoftheTranscriptome

• AdvancingtheClinicalApplicationsofRNA-SeqTechnology

2016

RNA-Seq 2016 SanFrancisco| April 26-28, 2016

Paul Rejto Head of Precision Medicine, Oncology Research Unit Pfizer

Yasuhiro FunahashiSenior Director, Biomarkers and Personalized Medicine Core Function UnitEisai

®

Chris MasonPrincipal Investigator and Associate ProfessorWeill Cornell Medical College

Ganesh Sathe Head of DNA SequencingGSK

Dongliang Ge Director, Computational Biology Gilead Sciences

Garry NolanProfessor, Microbiology & ImmunologyStanford University

@RNASeq_Summit

RNA-Seq Forum

1 6

3 8

2 7

4 9

5 10

Welcome to RNA-Seq 2016

Tel: +1 212 537 5898 Email: [email protected]

RNA-Seq 2016 San Francisco | April 26-28, 2016

@RNASeq_Summit

Realize the Practical Applications of RNA-SeqIn an industry that is constantly evolving, the integration and application of RNA-Seq technologies to improve drug discovery and development is gaining significant momentum.

RNA-Seq 2016 will help expert scientists, bioinformaticians and business leaders devise collaborative solutions to streamline technology and maximize the practical applications of RNA-Seq.

Critically, this year’s agenda has been designed specifically for the RNA-Seq community by fore-thinkers

in the industry with a greater focus on single-cell RNA-Seq, bioinformatics approaches and the clinical applications of RNA-Seq. By engaging with our expert speaker line-up, you will get the chance to hear the most up to date case studies, intellectual insight and be part of this thought provoking discussion.

Join the 4th annual RNA-Seq meeting to evaluate the latest advances in RNA-Seq, and discover how to fully utilize this technology to advance disease understanding and therapeutic intervention.

Harness the full potential of single-cell RNA-Seq to revolutionize the way we approach disease research

Implement specific bioinformatic systems for accurate analysis of clinical genomic studies

Top 10 Reasons to Attend RNA-Seq 2016

Develop analytical strategies to accurately interpret the vast complexity of the transcriptome and efficiently source the most valuable information

Successfully utilize metatranscriptomics to advance progression in microbiome disease research

Identify innovative, cutting edge methodologies to improve single-cell sequencing throughput and efficiency

Engage in debate with bioinformaticians and biologists to streamline the RNA-Seq process from the bench to the computer

Understand how to effectively develop RNA-Seq technologies into clinically applicable tools

Identify methods of commercializing RNA-Seq for biomarker detection and as a clinical diagnostic tool

Successfully integrate RNA-Seq with the other omic studies to generate combinatorial strategies for furthering disease understanding

Overcome the shortfalls in current RNA-Seq technologies to drive the evolution of cheaper and more efficient systems

Someofthebrightestmindsandindustryleadersingenomicsforaseriesofilluminatingseminarsandbeneficialmeetings. Bina Technologies RNA-Seq Attendee

RNA-Seq Forum

Speakers

Tel: +1 212 537 5898 Email: [email protected] @RNASeq_Summit

RNA-Seq 2016 SanFrancisco| April 26-28, 2016

Yasuhiro FunahashiSenior Director, Biomarkers & Personalized Medicine Core Function UnitEisai

Jeff BrockmanPrincipal ScientistHill’s Pet Nutrition

Tim MercerLab Head, Transcriptomic ResearchGarvan Institute of Medical Research

Alex Shalek,Assistant Professor of Health Sciences & TechnologyMIT

Alex MackenziePrincipal Investigator, Apoptosis Research Centre CHEO Research Institute

Zoltan DezsoPrincipal Scientist, Human Biology & Data Sciences EngineEisai

Magnolia BostickScientist IIITakara Clontech

Jamie HillSenior Bioinformatics ScientistQIAGEN

Saumya PantHead of Sequencing TechnologiesBristol-Myers Squibb

Xiang (Sean) Yao Principal Scientist CS - Computational & System Biology Janssen

Alex Pollen Damon Runyon Postdoctoral Fellow UCSF

Karsten ZenglerAssociate Professor, Division of Host-Microbe Systems & TherapeuticsUniversity of California, San Diego

Kejie LiComputational BiologistBiogen Idec

Jadwiga BienkowskaDirector, Computational BiologyPfizer

Josh KaminkerSenior Scientist, Bioinformatics & Computational Biology Genentech

Garry NolanProfessor, Microbiology & ImmunologyStanford University

Jin JenCo-Director, Genome Analysis Core, Medical Genome FacilityMayo Clinic

Dongliang GeDirector, Computational BiologyGilead Sciences

Kelli Bramlett Leader RNA Sequencing Applications Team, Life Sciences Solutions Thermo Fisher Scientific

Stefan McDonough Senior Director & Head of Neurogenetics Pfizer

Paul Rejto Head of Precision Medicine, Oncology Research Unit Pfizer

Ganesh Sathe Head of DNA SequencingGSK

Jean-Noel Billaud Principal ScientistQIAGEN

Chris MasonPrincipal Investigator & Assistant ProfessorWeill Cornell Medical College

RNA-Seq Forum



@RNASeq_Summit

8.20 Chair’s Opening Remarks

8.30 Keynote Presentation: Towards a Cellular & Molecular Resolution Map of Cerebral Cortex Development • Creating a cellular resolution map of gene expression in the developing human

neocortex to unravel the diversity of neuronal lineages and to support strategies for targeting and replacing specific cell types in the brain

• Analyzing gene expression across single cells to identify the outer subventricular zone radial glia preferentially express genes that may help to establish a self-sustaining proliferative stem cell niche

• Developing strategies to integrate data from single cell genomics with studies of morphology, position, cell behavior, developmental fate potential, and physiology

Alex Pollen, Damon Runyon Postdoctoral Fellow, UCSF

The Single-Cell RNA-Sequencing Revolution

9.00 Addressing Cancer Heterogeneity at the Single-Cell Level • Effectively utilizing single-cell RNA-Seq to elucidate tumor heterogeneity• Identifying epigenetic drivers of gene expression heterogeneity in cancer using single-

cell RNA-Seq• Efficiently analyzing and integrating transcriptional and epigenetic data in cancer

genomics research

Chris Mason, Principal Investigator and Associate Professor, Weill Cornell Medical College

9.30 Successfully Deconvolving Heterogeneous Systems Using Single-Cell RNA-Seq to Increase Disease Understanding • Improving understanding of cellular heterogeneity in the context of disease progression• Identification of cell differentiation with relevance to homeostasis and disease

pathogenesis• Analyzing the discovery of detailed cellular phenotypes to drive target identification and

therapeutic discovery

Alex Shalek, Assistant Professor of Health Sciences & Technology, MIT

10.00 Morning Refreshments & Speed Networking

11.00 Utilizing Single-Cell RNA-Seq For Fluid Biopsies Analysis • Deploying single-cell RNA-Seq for clinically accurate analysis of disease biopsies• Overcoming the hurdles of analyzing biofluid RNA samples with single-cell sequencing• Adapting experimental design and analytical methods to accommodate for biofluid RNA

sample input• Identification of current obstacles to single-cell RNA-Seq to streamline single-cell

RNA-Seq pipelines

Saumya Pant, Head of Sequencing Technology, Bristol-Myers Squibb

11.30 The Billion Cell Barcode Revolution• Harnessing split pool synthesis combinatorial chemistry as an alternative approach

in single-cell sequencing to barcode billions of cells without cellular isolation• Understanding how to successfully integrate split pool synthesis into an single-cell

RNA-Seq pipeline• Applying this revolutionary protocol in a disease specific context

Garry Nolan, Professor, Microbiology & Immunology, Stanford

12.00 Networking Lunch

Tackling Functional Transcriptome Complexity

1.00 Systematic Integration of RNA-Seq Data & Application to Drug Discovery Research• Integration internal and external RNA-Seq data, such as GTEx and ENCODE, through

consistent data processing and cross-linking• Multi-tier management of different RNA-Seq data types and access levels• Application of integrative RNA-Seq analysis to drug discovery, especially in various

aspects of target identification and validation

Xiang (Sean) Yao, Principal Scientist, CS - Computational and System Biology, Janssen

1.30 Overview of RNA-Seq Applications in Cancer Drug Discovery• Utilizing RNA-Seq in cancer drug discovery will be reviewed with applications to

target discovery, undercovering mechanisms of resistance, and providing insight into predictive markers for response to therapy

• Analyzing future directions and new applications including liquid biopsies, rare cell populations and poor quality tissue

Paul Rejto, Head of Precision Medicine, Oncology Research Unit, Pfizer

Conference Day One, April 27, 2016

RNA-Seq Forum



@RNASeq_Summit

2.00 Defining RNA Quality Control Metrics to Improve the Study of Full Transcriptional Complexity• The design, manufacture and validation of synthetic genes for bioinformatics analysis

of gene expression, transcript assembly and fusion gene diagnostics• Comprehensive analysis of human chromosome 21: detailing the full extent of

transcriptome size and complexity• Identification of fundamental distinctions between coding and non-coding gene

organisation, splicing and evolution

Tim Mercer, Lab Head, Transcriptomic Research, Garvan Institute of Medical Research

2.30 RNA-Seq Simplified! Targeted NGS Approaches to RNA Analysis • Discussing the use of Ion AmpliSeq™ technology for targeted RNA analysis • Analysis of data confirming high sensitivity, broad dynamic range and

assay robustness • Utilizing this approach for gene pathway analysis, gene fusion detection, and

transcriptome analysis

Kelli Bramlett, Leader, RNA Sequencing Applications Team, Life Sciences Solutions, Thermo Fisher Scientific

2.40 Using RNA-Seq to Study the Gastrointestinal Tract of the Dog • Addressing RNA integrity and endogenous RNAse expression in the upper sections

of the GI tract• Defining functional compartments of the GI tract through utilization of gene

expression patterns• Studying the correlation between specific mRNA expression levels and attachment of

gut microflora

Jeff Brockman, Principal Scientist, Hill’s Pet Nutrition

3.10 Afternoon Refreshments & Networking3.40 NGS & RNA-Seq in Cancer Immune Therapy

• Utilizing RNA-Seq to Study Protein-RNA interactions• Understanding how RNA-Seq can be used to study the impact of differential exon

expression on protein function • Employing RNA-Seq in conjunction with other sequencing methods for the

identification and observation of protein-RNA interactions in subcellular detail

Jadwiga Bienkowska, Director, Computational Biology, Pfizer

4.10 Deciphering the Cellular Complexities of Neurodegenerative Disease using RNA-Seq• Developing novel methods to purify specific populations of cells from whole brain• Performing RNA-Seq analysis using low quantity and low quality RNA• Transcriptomic analysis identifies cell specific expression and splicing changes in

neurodegenerative disease

Josh Kaminker, Senior Scientist, Bioinformatics & Computational Biology, Genentech

4.40 Panel Discussion: The Significance of Transcriptome Complexity• Evaluating RNA sequencing technologies and bioinformatic tools that resolve

transcriptome complexity.

• Debating the functional importance of pervasive transcription, long noncoding RNAs, and isoform diversity generated by extensive alternative splicing.

• Discussing the role of transcriptome complexity in evolution, development and disease

Tim Mercer, Lab Head, Transcriptomic Research, Garvan Institute of Medical Research

Alex Shalek, Assistant Professor of Health Sciences and Technology, MIT

Jeff Brockman, Principal Scientist, Hill’s Pet NutritionJosh Kaminker, Senior Scientist, Bioinformatics & Computational Biology, Genentech

Alex Pollen, Damon Runyon Postdoctoral Fellow, UCSF

5.20 Round Table SessionThis session will focus on devising solutions that cannot be obtained in presentation format, and will give you actionable takeaways to build a more holistic understanding of the field. Access the critical information that is only obtainable through frank and open discussion around crucial topics in the field. Shape the debate around the following topics:• How many cells do you need? – e.g. What are the drivers of the quantity of single cells you need to look at for your

experiment

• Single Cell RNA Seq Bioinformatics

• The power of full length transcript RNAseq – e.g. when to run full length transcript vs 3’ end counting to answer you biological question

6.20 Chair’s Closing Remarks

6.30 Networking Drinks Reception hosted by Fluidigm

®

®

RNA-Seq Forum



@RNASeq_Summit

8.50 Chair’s Opening Remarks

Analyzing the Clinical Applications of RNA Sequencing

9.00 Panel Discussion: Debating the Clinical Applications of RNA-Seq• Understanding the approval standards for clinical applications of RNA-Seq• Revamping the regulatory system to support the innovation and application of RNA-

Seq in the clinic• Defining the regulatory framework to identify the procedures for delivering clinically

useful RNA-Seq products• How to best analyze, interpret and present RNA-Seq data to maximize a clinically

relevant output• Incorporating RNA-Seq into clinical management and practices: identifying how to

best utilize RNA-Seq in the clinic

Ganesh Sathe, Head DNA Sequencing, GSK

Stefan McDonough, Executive Director, Research, Amgen

9.45 Utilizing RNA-Seq for Translational Research to identify Biomarker for Anticancer Agents Targeting Tumor Microenvironment• Employing RNA-Seq for cancer biomarker research to target tumor

microenvironment • Issues of RNA-Seq analysis and targeting approach with other methods to promote

translation science in clinical biomarker • Discussing the utility of RNA-Seq analysis based on examples of the translational

research for our anticancer drugs

Yasuhiro Funahashi, Senior Director, Biomarkers and Personalized Medicine Core Function Unit, Eisai

10.15 Harnessing the Potential of RNA-Seq as a Clinical Diagnostic Tool• Employing transcriptome profiling for disease analysis and compound verification• How to best use differential gene expression signatures to identify small molecules

for compound screening• Utilizing RNA-Seq technology for accurate profiling and analysis of ALS

neurodegenerative disease

Ganesh Sathe, Head DNA Sequencing, GSK

10.45 New Applications Leveraging RNA Sequencing using SMART Technology• Three new applications for low input RNA analysis• Using SMART technology to generate libraries for RNA profiling for:

• Small RNAs• TCR (T cell receptor) • Single cells using the Fluidigm C1

Magnolia Bostick, Scientist III, Takara Clontech

10.55 Morning Refreshments & Networking

11.30 Overcoming RNA Quality Issues to Enable High Quality Whole Transcriptome Sequencing• Critical factors affecting the quality of RNA in clinical and research settings• Optimized protocols for RNA-Seq using challenging and partially degraded samples• Clinical applications of RNA-Seq to enhance cancer diagnosis and

treatment stratification

Jin Jen, Co-Director, Genome Analysis Core, Mayo Clinic

12.00 Harnessing RNA-Seq in Drug Repurposing for Rare Genetic Disorders • Utilizing RNA-Seq to validate specific rare diseases as potential candidates for drug

repurposing programs• Devising analytical strategies to identify potential drugs that transcriptionally modulate

specific disease genes• Proving efficacy of potentially repurposable drugs and the restoration of normal genetic

function using RNA-Seq

Alex Mackenzie, Principal Investigator, CHEO Research Institute

Conference Day Two, April 28, 2016

RNA-Seq Forum



@RNASeq_Summit

12.30 Networking Lunch

1.30 Overcoming Bioinformatic Challenges in Clinical Genomics• Identifying the key big data issues in drug discovery and development

• Choosing a big data strategy for biomarker development

• Discussing common pitfalls when planning an NGS led study

• Best practices in the evaluation of the quality of NGS data

Dongliang Ge, Director Computational Biology, Gilead Sciences

2.00 Application of Single Cell RNA-Seq on Clinical Biopsy Material at Biogen• Benchmarking study of the comparison of RNA-Seq to other profiling platforms

• Findings of single cell RNA-Seq analysis of clinical biopsy sample

• For extreme low amount of biopsy sample, reconstituting single cell RNA-Seq profiles to bulk sample like profile as an alternative

Kejie Li, Computational Biologist, Biogen Idec

2.30 Afternoon Refreshments & Networking

3.00 Utilizing RNA-Seq Data for Biomarker Research in Cancer Immunotherapy• Identifying the immunophenotypes of different types of cancer by applying

computational methods on large scale RNA-Seq data

• Exploring how cancer immunophenotyping supports patient stratification and biomarker research in cancer immunotherapy

• Understanding the relationship between cancer immunophenotypes with immune genes and signaling pathways based on RNA-Seq expression profiling

Zoltan Dezso, Principal Scientist, Human Biology & Data Sciences Engine, Eisai

3.30 Panel Discussion: Creating Efficient Collaborations Between Bioinformaticians & Biologists to Harmonize RNA-Seq Procedures• Streamlining the RNA-Seq process between the bench and computer

• Matching experimental design and analytical strategies to accurately and efficiently interpret RNA-Seq data

• How to fully utilize sequencing and analysis of the transcriptome to inform disease understanding and drug discovery and development

• Improving our understanding of the transcriptome and developing better analysis strategies to deal with the sheer amount of transcriptional complexity

• Debating methods to make sequencing data analysis simpler, faster and cheaper

• Shifting towards a more targeted analytical approach defined by disease context and specific sequencing application

Paul Rejto, Head of Precision Medicine, Oncology Research Unit, Pfizer

Dongliang Ge, Director, Computational Biology, Gilead Sciences

Zoltan Dezso, Principal Scientist, Human Biology & Data Sciences Engine, Eisai

4.15 Chair’s Closing Remarks

4.20 End Day Two & Close of Conference

Excellentpanelofspeakersprovidingacomprehensiveoverviewofthefield

Vertex PharmaceuticalsRNA-Seq Attendee

RNA-Seq Forum



@RNASeq_Summit

Pre- Conference Workshop - A

The concept of a liquid biopsy has been around for some time, but is now fast becoming the leading technology for new diagnostics to detect early stage cancer resulting in more successful treatment, and to monitor cancer progression after treatment. While much of the focus in liquid biopsy has been on sequencing the DNA circulating in the patient’s blood, a recent paper in Nature Cell Biology entitled “Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver” researchers are focusing on exosomes circulating in the bloodstream; specifically the RNA contained within these exosomes. Pancreatic cancer is one of the most lethal cancers due in part to the difficulty in early diagnosis and treatment. Researchers believe sequencing RNA from tumor derived exosomes circulating in the patient’s blood could lead to early diagnosis and treatment. This workshop will include in-depth coverage of the bioinformatics solutions used to analyze and interpret RNA-sequencing results from these exosome experiments providing additional hypothesis on regulatory networks and potential isoforms of biological significance.

By attending this workshop you learn about and discuss the following:

• Take a deep dive and understand how to optimize the analysis of RNA-sequencing results to get the most out of each RNA-seq experiment

• Standardize RNA-sequencing data analysis using industry leading algorithms and statistical testing

• Understand scalable approaches to sequencing data analysis and optimize the ROI across the organization for sequencing experiments

• Evaluate a biologist approach to streamlining R NA-sequencing alignment and analysis using configured workflows for the fast track to biological interpretation

• Analyze exosome gene expression signatures to pinpoint significant genes associated with early detection of pancreatic cancer

• Identify significantly differentially expressed isoforms and their association to pancreatic cancer

• Generate novel regulatory networks as hypotheses suggesting drivers of the expression changes observed in these tumor producing exosomes to better understand pancreatic cancer drivers.

Transcriptome Analysis of Pancreatic Cancer Exosomes Reveal Pathways & Biological Processes Involved in Metastatic Progression

Date: April 26, 2016 | Time: 9:00am – 1:00pm

Workshop leaderDr. Jamie Hill Senior Bioinformatics Scientist QIAGEN

Workshop leaderDr. Jean-Noel Billaud Principal Scientist QIAGEN

Jamie Hill received a Master’s degree in Physics and a PhD in membrane protein structure prediction under the supervision of Professor CM Deane in the Statistics department of the University of Oxford. In 2014 he was awarded a Marie Curie postdoctoral fellowship at QIAGEN Aarhus. Today he is the Product Owner of QIAGEN’s CLC Genomics Workbench.

Jean-Noel Billaud, Ph.D. is Principal Scientist at Qiagen Bioinformatics. He joined Ingenuity Systems (now QIAGEN) in 2008 as staff scientist for in silico research program in oncology and infectious diseases. Jean-Noel Billaud holds a Ph.D. in Blood Cell Biology from Paris VII, and has done his post-doctoral work at the Scripps Research Institute (San Diego, CA).

RNA-Seq Forum



@RNASeq_Summit

Pre- Conference Workshop - B

In recent years the role of the microbiota in health and disease is a field of research that has exploded with interest and opportunity. We now have a better understanding of how changes to the composition of our natural microbiome and their products impacts upon the initiation and development of disease. This has unlocked exciting new avenues for therapeutic intervention.

In order to fully harness these new avenues of treatment, we must first advance our understanding of the specific role of microbiome communities in the progression of disease. Karsten Zengler will spearhead this dynamic and interactive session focussed on harnessing the power of RNA sequencing to provide detailed insight into the composition and function of the microbiota in a disease specific context. By attending this workshop, you will learn about and debate the following:

• Analyzing microbiome signatures: identification of gene expression patterns in complex microbial communities

• Deciphering the data: identifying strategies to maximize value output from microbiome RNA sequencing

• On the origin of species: delineating and attributing patterns of gene expression within the microbiome community

• Interpreting microbiota gene expression profiles to detail specific impacts on health and disease

• Algorithm refining and streamlining to increase the speed of analysis and subsequent application of RNA sequencing in microbiome research

• Clinically applying metatranscriptomics as a taxonomic biomarker and diagnostic tool

• Developing gold standard universal microbiome RNA sequencing protocols to aid reproducibility and the verification of microbial influence in disease progression

• Applying metatranscriptomics to guide drug discovery and development

• Creating accurate software packages for Prokaryotic RNA sequencing analysis

Attend this workshop to delve extensively into the subject matter, collaborate with fellow experts in the field, and hear a multitude of view points and experiences. You will leave better equipped to effectively utilize RNA sequencing to drive your microbiome disease research.

Successfully Utilizing Metatranscriptomics to Advance Progression in Microbiome Disease Research

Date: April 26, 2016 | Time: 2:00pm - 5:00pm

Workshop leaderKarsten Zengler Associate Professor, Division of Host-Microbe Systems & Therapeutics University of California, San Diego

Karsten Zengler is Associate Professor in the Department of Pediatrics, Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego and member of the leadership team of the Center for Microbiome Innovation.

Prof. Zengler has more than 15 years of experience in the fields of microbiology and systems biology. He worked for seven years in the biotechnology industry where he led a team of scientists to pioneer the high-throughput cultivation for the isolation and recovery of previously unculturable microorganisms. His work has focused on microbial ecology and understanding

microorganism interactions with each other, their environment and their host. He spearheaded the field of community systems biology where he combined his knowledge in microbial physiology and molecular biology with computational biology to discover new physiological capabilities, regulatory effects, and novel mechanisms of interaction. Dr. Zengler is author and co-author of more than 50 research articles and reviews as well as editor of the book “Accessing Uncultivated Microorganisms”. He founded several companies and is on the advisory board of different companies and institutions

RNA-Seq Forum

Commercial Partners



@RNASeq_Summit

®

Clontech

Clontech’s comprehensive collection of SMARTer® NGS kits is built on core SMART® technology, a powerful process that provides the ability to read full-length transcript information. With years of experience and a strong focus on improving the process of RNA-seq library preparation and the quality of data produced from every sample, this highly sensitive family of RNA-seq products is constantly growing in order to fulfill more demanding research needs.

www.clontech.com

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit

www.thermofisher.com

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 20 countries.

www.qiagen.com

Fluidigm

Fluidigm creates and manufactures innovative technologies and life-science tools designed to revolutionize biology through a relentless pursuit of scientific truth. Its core technologies are based on microfluidics and mass cytometry, and enable the exploration and analysis of individual cells, as well as the industrial application of genomics.

Fluidigm partners with life science researchers and enterprises to provide simplified workflows for genomics and proteomics applications. Whether your quest is to understand the profiles and functions of single cells or to meet high-throughput data demands of a production-scale laboratory, you’ll find a solution at

www.fluidigm.com

Spotlight Partner

Spotlight Partner

Workshop Partner

Lead Partner

Exhibition Partner

Genialis

Genialis builds software that empowers the biologist or clinician to explore her data autonomously. Genialis Platform is a complete ecosystem for NGS data management, analysis, visualization and collaboration. The Platform boasts Real Time Interactive Visualizations, a technology we developed to enhance the user experience and improve the efficiency of data exploration and discovery.

www.genialis.com

RNA-Seq Forum

Commercial Partners

Contact Us

Contact

Diane McKenna Portfolio Director - Genomics


Who you will meet...

C-Level

Director Level

Academia

Principal Scientist

64%20%

30%35%

15%

Previous Attendance by

Seniority

Pharma

Academia

Solution Providers

20%50%

30%

20%

Predicted Attendance by

Sector



@RNASeq_Summit

Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including two of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot and Genomics England’s 100,000 Genomes Project. The company’s 187 experts work from its Cambridge, MA headquarters and offices in Belgrade, London and San Francisco.

www.sbgenomics.com

Dolomite

Dolomite develops and manufactures innovative, open and versatile droplet systems for handling tens of thousands of single cells. Applications include high throughput single cell RNA sequencing, T Cell Receptor sequencing, high throughput antibody isolation, and encapsulation of cells in hydrogel beads for culture or enzymatic reactions. We offer modular, scalable systems ideal for Single Cell RNA-Seq and a range of chips, and installation and training.

www.dolomite-microfluidics.com

Exhibition Partner Exhibition Partner

RNA-Seq Forum

Venue and Accommodation

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

Terms & Conditions

Register

Event Prices

Pricing & Venue

Industry

Register & Pay before Friday March 18, 2016 Standard Prices

Conference + 2 Workshops $3597 (Save $500) $3797 (Save $300)

Conference + Workshop $3098 (Save $300) $3198 (Save $200)

Conference Only $2499 (Save $200) $2699

Workshop (each) $699

Academic

Register & Pay before Friday March 18, 2016 Standard Prices

Conference + 2 Workshops $2197 (Save $400) $2397 (Save $200)

Conference + Workshop $1898 (Save £200) $1998 (Save $100)

Conference Only $1499 (Save $100) $1599

Workshop (each) $499



@RNASeq_Summit

The Marker Hotel 501 Geary Street San Francisco California 94102Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

www.rna-seqsummit.com/register Tel: +1 212 537 5898 Email: [email protected]: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

• 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegatesPlease note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Team Discounts*

4th rna-seq san francisco april 26-28 event guide

Health & Medicine